

Press release

Merger & Acquisition

1st of July, 2022



Larka provided Elyan with a **Commercial Due Diligence** to support its acquisition of **Oncodesign.**



Advised by **Larka**

Larka is very pleased to announce it performed the **Commercial Due Diligence** to support Elyan Partners' acquisition of a majority stake in the CRO Business Unit of leading French Biopharmaceutical company **Oncodesign**.

Elyan Partners – acting as the exclusive advisor to Edmond de Rothschild Equity Strategies IV, a Private Equity fund – enters into exclusive negotiations for the acquisition of a majority stake in the capital of Oncodesign (Service) followed by the filing of a simplified takeover offer. Oncodesign (Service) is the Contract Research Organization (CRO) service BU of Oncodesign, a Dijon-based Biotech and Service company.

How Did Larka Support Elyan Acquisition Process?

This Commercial Due Diligence provided Elyan Partners with **key insights and recommendations**, giving Larka a decisive role in the overall decision-making process, and in turn, the upcoming acquisition of Oncodesign by the Paris-based Private Equity firm.

As for all of Larka's Merger and Acquisition services, this Commercial Due Diligence process leveraged our extensive life sciences industry and biopharmaceuticals knowledge – in this case the **Drug Discovery universe** – to provide Elyan with a comprehensive picture of Oncodesign's:

- Services and core value proposition
- Customer environment and market feedbacks
- Positioning in the competitive landscape
- Business Plan review and growth avenues



“We are thrilled of our continuous partnership with the Larka team who provided us with great commercial and strategic insight. With their assistance, we were able to quickly firm up our conviction on the asset and outline our strategic roadmap. We look forward to working with Pierre-Anthony, Adrien and all the deal team members on our future projects.”

Jean-François Félix, Maxence de Vienne & Vincent Manès
Partners – Elyan Partners

Contact Us

Pierre-Anthony Brioir
Senior Director
+33 650 630 286
pabrioir@larka.com

Adrien Chalmont
Senior Manager
+33 621 006 115
achalmont@larka.com

Discover Related Services

Commercial Due Diligence
[Visit website ▶](#)

Integrated Due Diligence
[Visit website ▶](#)

Operational Due Diligence
[Visit website ▶](#)

Technical Due Diligence
[Visit website ▶](#)

About Elyan Partners

A partner member of Edmond de Rothschild Private Equity, Elyan Partners SAS (“Elyan”) is a financial investment advisor, and the exclusive advisor for the ERES funds and advisor to the Privilege funds with the Edmond de Rothschild Group. Edmond de Rothschild Equity Strategies IV SLP (“ERES IV”) invests in medium-sized companies in Europe and North America, mainly in four themes: the biotech ecosystem, e-commerce, financial services and new consumers.

Edmond de Rothschild Private Equity is the commercial name of the Private Equity entities of the Edmond de Rothschild Group and manages more than CHF 3.4 billion in assets under management. With an entrepreneurial approach to finance and supported by strong convictions, Edmond de Rothschild Private Equity builds and develops differentiated investment strategies that provide a sustainable response to environmental and social issues. Founded in 1953, the Group had nearly CHF 178 billion in assets under management as of December 31, 2021, 2,500 employees and 29 locations around the world.

For more information, please visit www.elyan.com

About Oncodesign

Oncodesign is a biopharmaceutical company dedicated to precision medicine, founded in 1995 by its current CEO and majority shareholder, and has been listed on Euronext Growth Market since April 2014. Its mission is the discovery of effective therapies to fight cancer and other diseases without therapeutic solutions. With its unique experience acquired by working with more than 1 000 clients, including the world’s largest pharmaceutical companies, along with its unique technological platform combining Artificial Intelligence, state-of-the-art medicinal chemistry, pharmacology, regulated bioanalysis, medical imaging, Oncodesign is able to select new therapeutic targets, design and develop potential preclinical candidates through to clinical phases. Oncodesign has configured its organization to offer innovative services to its customers and to license its proprietary molecules. Applied to kinase inhibitors, which represent a market estimated at over \$65 billion by 2027 and accounting for almost 25% of the pharmaceutical industry’s R&D expenditure, Oncodesign’s technology has already enabled the targeting of several promising molecules with substantial therapeutic potential, in oncology and elsewhere, along with partnerships with global pharmaceutical groups. Oncodesign is based in Dijon, France, in the heart of the town’s university and hospital hub, and within the Paris-Saclay cluster. Oncodesign has 240 employees within 3 Business Units (BU): Service, Biotech, Artificial Intelligence and subsidiaries in Canada and the USA.

For more information, please visit www.oncodesign.com

About Larka

Larka is a management consulting firm, exclusively dedicated to the Biotech and Pharma industry. We assist small Biotech or large Pharma companies, Contract Services Providers or Equipment Suppliers, Venture Capital or Private Equity firms, in their development or in managing complex situations. Active in Technical, Organizational, Commercial and Strategic operations, Larka has developed a unique combination of expertise which covers CMC & Outsourcing activities, Operational & Commercial excellence, Marketing & Sales, Corporate Strategy and M&A.

For more information, please visit www.larka.com



Larka